Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

NCT05775848 is registered in ClinicalTrials.gov with ML Bio Solutions, Inc. as lead sponsor.

NCT NCT05775848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05775848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
Lead sponsor
ML Bio Solutions, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 31, 2023
Completion date
September 30, 2027
Enrollment
112 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

limb-girdle muscular dystrophy type 2i (lgmd2i)